TP53 and small cell lung carcinoma: Unlike non-SCLC, which is commonly associated with targetable kinase mutations, SCLC biology is less evidently tractable, driven instead by nearly uniform loss of tumour suppressors TP53 and RB1 (refs 22, 23).